# US 2026/0166103 A1 · Cannabigerolic acid (cdga) derivatives and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0166103 A1
- Document ID: US20260166103A1
- Status: Published application
- Kind: A1
- Application number: 19/529,854
- Filed: 2026-02-04
- Published: 2026-06-18
- Earliest claimed: 2020-06-03
- Assignees: Epm (IP), Inc.; Yissum Research Development Company of the Hebrew University of Jerusalem
- Applicants: Epm (IP), Inc.; Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
- Inventors: Reshef Swisa; Anat Iosub-Amir; Ron Shaharabani; Raphael Mechoulam; Natalya M. Kogan
- Web page: https://patentgrep.com/patent/US20260166103A1

## CPC

- A61K 36/3482: {Cannabis}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07C 65/28: having unsaturation outside the aromatic rings
- C07C 69/92: with etherified hydroxyl groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention provides novel compounds comprising cannabigerlic acid (CBGA) derivatives, including acids and esters, and uses thereof in the treatment of various diseases, disorders, conditions and symptoms.

## Claims

### Claim 1

A method of treating a disease, disorder or symptom amenable to treatment with cannabigerol (CBG), the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound represented by the structure of Formula (I),
wherein
R1 is selected from the group consisting of a hydrogen, a linear or branched unsubstituted or substituted C1-C15 alkyl, a linear or branched unsubstituted or substituted C2-C15 alkenyl, and a linear or branched unsubstituted or substituted C2-C15 alkynyl;
R2 is selected from the group consisting of a linear or branched unsubstituted or substituted C1-C15 alkyl, a linear or branched unsubstituted or substituted C2-C15 alkenyl, and a linear or branched unsubstituted or substituted C2-C15 alkynyl;
and stereoisomers, geometrical isomers, and salts thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the disease, disorder or symptom amenable to treatment with CBG is selected from the group consisting of Non-Alcoholic Fatty Liver Disease (NAFLD), chronic kidney disease (CKD), obesity, hyperglycemia, diabetes, metabolic syndrome and/or obesity related diseases.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the disease is obesity.

### Claim 4 (depends on 1)

The method according to claim 1, wherein R1 is a linear unsubstituted C1-C15 alkyl.

### Claim 5 (depends on 1)

The method according to claim 1, wherein R1 is methyl.

### Claim 6 (depends on 1)

The method according to claim 1, wherein R1 is hydrogen.

### Claim 7 (depends on 1)

The method according to claim 1, wherein R2 is a linear unsubstituted C1-C15 alkyl.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1-5, wherein R2 is a linear unsubstituted C5 alkyl.

### Claim 9 (depends on 1)

The method according to claim 1, which is represented by the structure of Formula (II),
and stereoisomers and salts thereof.

### Claim 10 (depends on 1)

The method according to claim 1, which is represented by the structure of Formula (III),
and stereoisomers thereof.

### Claim 11 (depends on 1)

The method according to claim 1, comprising the step of administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of the compound represented by the structure of Formula (I) and a pharmaceutically acceptable carrier or excipient.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the pharmaceutical composition further comprises at least one additional active ingredient, wherein the additional active ingredient comprises at least one additional cannabinoid compound.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the additional cannabinoid compound comprises a cannabigerolic acid (CBGA) ester represented by Formula (IV), a cannabinolic acid (CBNA) ester represented by Formula (V), a cannabidiolic acid (CBDA) ester represented by Formula (VI), a tetrahydrocannabinolic acid (THCA) ester represented by Formula (VII) or any combination thereof,
wherein
each of R3, R4, R5, R6, R7, R8, R9 and R10 is independently selected from the group consisting of a linear or branched, unsubstituted or substituted C1-C15 alkyl, a linear or branched, unsubstituted or substituted C2-C15 alkenyl, and a linear or branched, unsubstituted or substituted C2-C15 alkynyl;
one of the dashed lines in Formula (VII) represents a double bond and the other dashed line represents a single bond;
and stereoisomers and salts thereof.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the pharmaceutically acceptable carrier or excipient comprises at least one of a binder, a filler, a diluent, a surfactant or emulsifier, a glidant or lubricant, a buffering or pH adjusting agent, a tonicity enhancing agent, a wetting agent, a preservative, an antioxidant, a flavoring agent, a colorant, and a mixture or combinations thereof.

### Claim 15 (depends on 11)

The method according to claim 11, a form selected from the group consisting of tablet, pill, capsule, pellets, granules, powder, a wafer, coated or uncoated beads, lozenge, sachet, cachet, elixir, a depot system, an a patch, suspension, dispersion, emulsion, solution, syrup, aerosol, oil, ointment, suppository, a gel, and a cream.

### Claim 16 (depends on 12)

The method according to claim 12, wherein the additional cannabinoid compound is present in one or more extracts of a cannabis plant.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the cannabis plant extract is obtained from a strain selected from the group consisting of Cannabis sativa, Cannabis indica, Cannabis ruderalis, a hybrid strain, and combinations thereof.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the cannabis plant extract is obtained from a strain selected from the group consisting of a high-CBD strain, a high-THC strain, and a combination thereof.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the cannabis plant extract comprises at least one cannabinoid selected from the group consisting of cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), thereof and combinations thereof.
